Bavarian Nordic to test its Covid-19 booster against Pfizer/BioNTech shot in pivotal study
As Bavarian Nordic has made strides recently to beef up its smallpox vaccine manufacturing in the wake of new monkeypox cases, the company is also getting ready to evaluate its Covid-19 booster in a pivotal study. And it’s going after one of the heavyweights.
The Copenhagen-based company announced Thursday morning it will be pitting its Covid-19 booster shot against Pfizer and BioNTech’s booster, redesigning its Phase III study to include the comparator. Bavarian Nordic said the change will not impact its data readout timeline, expected before the end of the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.